Handok signs contract with Pfizer Pharmaceutical Korea to sell Viviant and DUAVIVE in Korea
Handok signed a sales contract with Pfizer Pharmaceutical Korea (Country Manager: Dongwook Oh) to sell in Korea the postmenopausal osteoporosis drugs Viviant and DUAVIVE, used for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.
Handok had already signed a contract with Pfizer Pharmaceutical Korea in 2014 for the joint sales of Viviant. Through this year’s contract, however, Handok became the sole seller of Viviant in all channels. Moreover, with the addition of DUAVIVE, Handok has strengthened its portfolio of products for women entering menopause.
Viviant (bazedoxifene acetate) is a type of selective estrogen receptor modulator (SERM) that is taken once a day to treat osteoporosis. It was launched in Korea in 2012 for the treatment and prevention of postmenopausal osteoporosis.
DUAVIVE (conjugated estrogens and bazedoxifene) is a tissue selective estrogen complex (TSEC) that is taken once a day. It is used to relieve moderate to severe symptoms of menopause or vasomotor symptoms in menopausal women with a uterus and also helps prevent postmenopausal osteoporosis.
Handok CEO Young-Jin Kim remarked, “Ever since 2014, when Handok was placed in charge of the sales of TOVIAZ and Viviant, we have maintained a strong partnership with Pfizer Pharmaceuticals Korea.” He further added, “We are happy to introduce an excellent product like DUAVIVE to Korea at this time, and we will do our best to help menopausal women lead healthier lives.”